
An announcement from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group is a pharmaceutical group. The release concerns CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting Nectin-4.
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CHJTF | CSPC Pharmaceutical Group | 1.12 | 0.13 | 13.06% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.12 | +13.06% |

An announcement from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group is a pharmaceutical group. The release concerns CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting Nectin-4.

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. During the nine months ended 30 September 2026, CSPC recorded unaudited revenue of RMB25,260 million, up 27.0% from

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group has officially initiated at the first centre in China a multi-centre, open-label Phase Ib/II trial

CSPC Pharmaceutical Group (CHJTF) is scheduled to report 3rd quarter earnings on 11/18/2026. Regarding Q3 estimates, Wall Street analysts expect CSPC Pharmaceutical Group to post earnings of CNH0.08 per share.

CSPC Pharmaceutical Group (CHJTF) is scheduled to report 3rd quarter earnings on 11/13/2026. Regarding Q3 estimates, Wall Street analysts expect CSPC Pharmaceutical Group to post earnings of CNH0.08 per share.

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group is a pharmaceutical developer and manufacturer focused on innovative medicines, with this program targeting respiratory disease treatment

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group Limited is a Hong Kong-listed company; the announcement does not provide details on its industry,

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group is a pharmaceutical company that develops medicines, with a focus in this announcement on innovative oncology therapies.

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group has initiated the first China centre in a multi-centre Phase I/II clinical trial of SYS6062,

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group is a Hong Kong-listed pharmaceutical company focused on developing medicines, including Class 1 chemical drugs,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 24, 2027TBA | $12.15B | $0.02 | $1.05B | -1.94 | 10.37 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.